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Background
Oral fingolimod, a sphingosine-1-phosphate–receptor modulator that prevents the 
egress of lymphocytes from lymph nodes, significantly improved relapse rates and end 
points measured on magnetic resonance imaging (MRI), as compared with either pla-
cebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis.
Methods
In our 24-month, double-blind, randomized study, we enrolled patients who had re-
lapsing–remitting multiple sclerosis, were 18 to 55 years of age, had a score of 0 to 
5.5 on the Expanded Disability Status Scale (which ranges from 0 to 10, with higher 
scores indicating greater disability), and had had one or more relapses in the previ-
ous year or two or more in the previous 2 years. Patients received oral fingolimod at 
a dose of 0.5 mg or 1.25 mg daily or placebo. End points included the annualized 
relapse rate (the primary end point) and the time to disability progression (a second-
ary end point).
Results
A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse 
rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 
with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 
1.25 mg significantly reduced the risk of disability progression over the 24-month pe-
riod (hazard ratio, 0.70 and 0.68, respectively; P = 0.02 vs. placebo, for both compari-
sons). The cumulative probability of disability progression (confirmed after 3 months) 
was 17.7% with 0.5 mg of fingolimod, 16.6% with 1.25 mg of fingolimod, and 24.1% 
with placebo. Both fingolimod doses were superior to placebo with regard to MRI-
related measures (number of new or enlarged lesions on T2 -weighted images, gadolin-
ium-enhancing lesions, and brain-volume loss; P<0.001 for all comparisons at 24 months). 
Causes of study discontinuation and adverse events related to fingolimod included bra-
dycardia and atrioventricular conduction block at the time of fingolimod initiation, 
macular edema, elevated liver-enzyme levels, and mild hypertension.
Conclusions
As compared with placebo, both doses of oral fingolimod improved the relapse rate, the 
risk of disability progression, and end points on MRI. These benefits will need to be 
weighed against possible long-term risks. (ClinicalTrials.gov number, NCT00289978.)
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Fingolimod (fty720) is an oral sphin-gosine-1-phosphate–receptor modulator1 that is currently being evaluated for the treatment 
of multiple sclerosis. There is evidence that fin-
golimod acts by preventing lymphocyte egress from 
lymph nodes.2,3 This leads to a reduced infiltration 
of potentially autoaggressive lymphocytes into the 
central nervous system.4,5 Preclinical findings also 
suggest that fingolimod may promote neuropro-
tective and reparative processes within the central 
nervous system through modulation of sphin-
gosine-1-phosphate receptors expressed on neu-
ral cells.6-12
A 6-month, phase 2, placebo-controlled study13 
and its open-label extension study14 showed sus-
tained suppression, for up to 5 years, of both re-
lapse and inflammatory activity in patients re-
ceiving fingolimod. Furthermore, in a recently 
completed, 12-month, phase 3 study involving pa-
tients with relapsing–remitting multiple sclerosis 
(TRANSFORMS [Trial Assessing Injectable Inter-
feron vs. FTY720 Oral in RRMS]; ClinicalTrials 
.gov number, NCT00340834), reported elsewhere 
in this issue of the Journal, fingolimod reduced 
the relapse rate and disease activity as measured 
with the use of magnetic resonance imaging 
(MRI), as compared with a once-weekly, intra-
muscular injection of interferon beta-1a at a dose 
of 30 μg.15
In our phase 3, double-blind, placebo-controlled 
study, called FREEDOMS (FTY720 Research Eval-
uating Effects of Daily Oral therapy in Multiple 
Sclerosis), we investigated the effects of daily fin-
golimod treatment for 24 months on the relapse 
rate, disability progression, and MRI measures of 
inflammation, burden of disease, and tissue de-




Steering-committee members (listed in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org) collaborated with the 
sponsor, Novartis Pharma, to develop the proto-
col and monitor the ongoing study. Data were 
collected by the investigators and analyzed by the 
sponsor. All the authors had access to the data, 
participated in the data analysis and interpreta-
tion, and wrote the manuscript. All authors vouch 
for the accuracy and completeness of the data and 
the statistical analysis. All authors participated in 
the writing of the manuscript and approved the 
final manuscript before submitting it for publi-
cation.
Patients
Key eligibility criteria were an age of 18 to 55 years; 
a diagnosis of multiple sclerosis, according to the 
revised McDonald criteria16; a relapsing–remitting 
course17; one or more documented relapses in the 
previous year or two or more in the previous 
2 years; and a score of 0 to 5.5 on the Expanded 
Disability Status Scale (EDSS; which ranges from 
0 to 10, with higher scores indicating greater dis-
ability).18 Key exclusion criteria were relapse or 
corticosteroid treatment within 30 days before 
randomization, active infection, macular edema, 
diabetes mellitus, immune suppression (drug- or 
disease-induced), or clinically significant systemic 
disease. Interferon-beta or glatiramer acetate ther-
apy had to have been stopped 3 or more months 
before randomization.
The study was conducted in accordance with 
the International Conference on Harmonisation 
Guidelines for Good Clinical Practice19 and the 
Declaration of Helsinki.20 The protocol was ap-
proved by each site’s institutional review board; 
patients gave written informed consent before any 
study-related procedures were performed.
Study Design and Randomization
Patients were randomly assigned, in a 1:1:1 ratio, 
to receive oral fingolimod capsules in a dose of 
0.5 mg or 1.25 mg or matching placebo, once dai-
ly for 24 months. Randomization was performed 
centrally, with the use of a validated system and 
stratification according to site, with a block size 
of six within each site.
To ensure that all assessments remained unbi-
ased regarding the study-group assignments (i.e., 
unaffected by awareness of them), an independent, 
specially trained and certified21 examining neu-
rologist determined all the EDSS scores; this 
examining neurologist or a trained technician 
administered the Multiple Sclerosis Functional 
Composite (MSFC; comprising the average of the 
scores on the timed 25-foot walk, the 9-hole peg 
test, and the paced auditory serial-addition test 
with a 3-second interstimulus interval, with each 
converted to a z score [with the combined study 
population at baseline as the reference popula-
tion], with higher scores representing improve-
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ment).22 Another independent physician monitored 
patients for 6 or more hours after administration 
of the first dose of the study drug. MRI scans 
were analyzed at a central MRI evaluation center by 
radiologists who were unaware of the study-group 
assignments, and an independent data and safety 
monitoring board evaluated the safety and over-
all benefit–risk profiles.
Study Procedures and End Points
Clinical assessments were performed at screening 
and at randomization (baseline), and study visits, 
including safety assessments, were scheduled at 
2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 
months after randomization. The EDSS score was 
determined every 3 months, and the MSFC z score 
every 6 months. Standardized MRI scans were ob-
tained at the screening visit and at 6, 12, and 24 
months and were analyzed centrally at the Mul-
tiple Sclerosis–MRI Evaluation Center at the Uni-
versity Hospital in Basel, Switzerland.
The primary end point was the annualized re-
lapse rate, defined as the number of confirmed 
relapses per year. Relapses were verified by the 
examining neurologist within 7 days after the on-
set of symptoms. To constitute a confirmed re-
lapse, the symptoms must have been accompanied 
by an increase of at least half a point in the EDSS 
score, of one point in each of two EDSS functional-
system scores, or of two points in one EDSS 
functional-system score (excluding scores for the 
bowel–bladder or cerebral functional systems).
The key secondary end point was the time to 
confirmed disability progression, defined as an 
increase of one point in the EDSS score (or half 
a point if the baseline EDSS score was equal to 
5.5), confirmed after 3 months, with an absence of 
relapse at the time of assessment and with all 
EDSS scores measured during that time meet-
ing the criteria for disability progression.
Other secondary end points included the time 
to a first relapse, time to disability progression 
(confirmed after 6 months), changes in the EDSS 
score and MSFC z score23 between baseline and 
24 months, number of gadolinium-enhancing le-
sions, proportion of patients free from gadolin-
ium-enhancing lesions, number of new or enlarged 
lesions on T2-weighted MRI scans, proportion of 
patients free from new or enlarged lesions on T2-
weighted scans, volumes of hyperintense lesions 
on T2-weighted scans and hypointense lesions on 
T1-weighted scans, change in brain volume be-
tween baseline and 24 months, and safety and 
tolerability measures. Specifications of the ad-
verse-event monitoring procedure, as defined in 
the study protocol, were the same as those in 
TRANSFORMS and are detailed in the Supplemen-
tary Appendix, which also provides other method-
ologic details.
Statistical Analysis
For the primary end point, on the basis of data 
from a phase 2 study of fingolimod,13,24 the ex-
pected annualized relapse rate was 0.7 for the 
group receiving placebo and 0.42 for the group 
receiving 1.25 mg of fingolimod, with a common 
standard deviation of 1.06. We calculated that a 
sample of 1250 patients would provide 95% sta-
tistical power to detect a relative reduction of 40% 
or more in the annualized relapse rate with fingoli-
mod as compared with placebo, after 24 months. 
With this sample size, using a log-rank test and 
a two-sided α level of 0.05 (assuming a study-dis-
continuation rate of 25%13), we calculated that 
the study would have a statistical power of more 
than 90% to detect an absolute difference be-
tween the two groups of 12% in the proportion 
of patients with disability progression (confirmed 
after 3 months) at month 24, which was expected 
to be approximately 30% in the placebo group.
Both the intention-to-treat population and the 
safety population included all patients who had 
undergone randomization. The study tested two 
null hypotheses: that there were no differences in 
the annualized relapse rate between the group re-
ceiving fingolimod at a dose of 1.25 mg and the 
group receiving placebo or between the group re-
ceiving fingolimod at a dose of 0.5 mg and the 
group receiving placebo. The aggregate annual-
ized relapse rate was estimated by means of a 
negative binomial regression model with adjust-
ment for study group, country, number of relapses 
within 2 years before baseline, and EDSS score at 
baseline. The time to relapse or progression was 
estimated with the use of the Kaplan–Meier meth-
od.25 The times to disability progression (con-
firmed after 3 or 6 months) were compared in 
the main analysis by means of the log-rank test 
and in the supportive analysis by means of a Cox 
proportional-hazards model with adjustment for 
study group, country, baseline EDSS score, and 
age. To control for a type I statistical error, a pro-
spectively planned, hierarchical testing procedure 
was used to compare fingolimod with placebo re-
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garding the primary and key secondary end points, 
in the following order: the annualized relapse rate, 
first in association with 1.25 mg of fingolimod 
and next in association with 0.5 mg of fingolimod, 
and then the time to disability progression (con-
firmed after 3 months), first with 1.25 mg of 
fingolimod and next with 0.5 mg of fingolimod. 
Each test was performed with a significance level 
of 0.05. However, the next test was performed only 
when the preceding test was statistically signifi-
cant. Missing data were not imputed.
Safety analyses were summarized by means of 
descriptive statistics; inferential significance test-
ing was not performed. Statistical details for other 




From January 2006 through August 2007, a total 
of 1272 patients were randomly assigned to a study 
group (Fig. 1) at 138 centers in 22 countries (see 
the Supplementary Appendix for a list of the cen-
ters and principal investigators). Baseline charac-
teristics were similar across the three study groups 
(Table 1). In total, 1033 patients (81.2%) completed 
the 24-month study, with 945 (74.3%) still receiv-
ing the assigned study drug. The study drug was 
discontinued in proportionately fewer patients in 
the group receiving 0.5 mg of fingolimod (18.8%) 
than in the group receiving 1.25 mg of fingoli-
mod (30.5%) or in the placebo group (27.5%). 
Reasons for study-drug discontinuation are listed 
in Figure 1.
Efficacy
All clinical and MRI-related efficacy end points 
significantly favored both doses of fingolimod over 
placebo, and there were no significant differences 
in efficacy between the two fingolimod doses 
(Table 2).
Relapse
The aggregate annualized relapse rate (the pri-
mary end point) was lower with fingolimod at a 
dose of 0.5 mg (0.18) and fingolimod at a dose of 
1.25 mg (0.16) than with placebo (0.40), represent-
ing relative reductions of 54% and 60%, respec-
tively, in the annualized relapse rate (Table 2). As 
compared with placebo, both doses of fingolimod 
reduced the annualized relapse rate among pa-
tients who had not previously received disease-
modifying treatment as well as among those who 
had been treated previously (P<0.01 for all com-
parisons). In the fingolimod groups as compared 
with the placebo group, the time to a first relapse 
was longer (Fig. 2A), the risk of relapse was re-
duced, and proportionately more patients re-
mained free of relapse during the 24-month period 
(Table 2).
Disability
The time to disability progression, with confirma-
tion either after 3 months (the key secondary end 
point) or after 6 months, was longer with both 
fingolimod doses than with placebo (Fig. 2B and 
Table 2). Fingolimod reduced the risk of disabil-
ity progression, confirmed after 3 months, over the 
24-month study period (hazard ratios, 0.68 for the 
1.25-mg dose and 0.70 for the 0.5-mg dose). The 
cumulative probability of disability progression 
(confirmed after 3 months) was 17.7% for 0.5 mg 
of fingolimod, 16.6% for 1.25 mg of fingolimod, 
and 24.1% for placebo. Regarding disability pro-
gression that was confirmed after 6 months, the 
risk was also reduced with fingolimod over the 
24-month study period (hazard ratio, 0.60 with 
the 1.25-mg dose and 0.63 for the 0.5-mg dose), 
and the cumulative probability of progression was 
12.5% for 0.5 mg of fingolimod, 11.5% for 1.25 mg 
of fingolimod, and 19.0% for placebo. During the 
study period, the EDSS scores and MSFC z scores 
remained stable or improved slightly in the fingoli-
mod groups and worsened in the placebo group 
(Table 2).
MRI-Related End Points
Patients in either fingolimod group had signifi-
cantly fewer gadolinium-enhancing lesions than 
those in the placebo group at 6, 12, and 24 months, 
as well as fewer new or enlarged lesions on 
T2-weighted MRI scans at 24 months (Table 2). 
Proportionately more patients in the fingolimod 
groups than in the placebo group were also free 
from gadolinium-enhancing or new or enlarging 
lesions at these time points (Table 2 and Fig. 2C). 
The median volume of lesions on T2-weighted 
scans decreased between baseline and month 24 
with fingolimod but increased with placebo.
During the 24-month study period, changes 
in the volume of hypointense lesions on T1-weight-
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ed scans favored both doses of fingolimod over 
placebo (Table 2). In addition, reductions in brain 
volume were smaller with fingolimod.
Adverse Events
Similar proportions of patients (93 to 94%) in the 
three study groups were reported to have adverse 
events (Table 3); the events were mild to moder-
ate in severity in 82% of patients receiving 0.5 mg 
of fingolimod, 77% of those receiving 1.25 mg of 
fingolimod, and 77% of those receiving placebo. 
Adverse events that led to discontinuation of the 
study medication (including abnormal laboratory-




1564 Patients were assessed for eligibility
292 Were excluded
212 Did not meet inclusion criteria
41 Declined to participate
45 Were excluded for other reasons
429 Were assigned to receive
1.25 mg of fingolimod daily and
were included in intention-
to-treat and safety analyses
418 Were assigned to receive
placebo and were included in
intention-to-treat and safety
analyses
333 Completed the study
298 Were still receiving the
study drug
35 Had discontinued the
study drug
332 Completed the study
303 Were still receiving the
study drug
29 Had discontinued the
study drug
425 Were assigned to receive
0.5 mg of fingolimod daily and
were included in intention-
to-treat and safety analyses
96 Discontinued the study 
30 Withdrew consent
22 Had an adverse event
20 Had an abnormal laboratory
value
13 Had an unsatisfactory
therapeutic effect
5 Had a protocol violation
3 Were lost to follow-up
2 Had an abnormal test
procedure result
1 Died
86 Discontinued the study 
28 Withdrew consent
18 Had an adverse event
1 Had an abnormal laboratory
value
25 Had an unsatisfactory
therapeutic effect
4 Had a protocol violation
7 Were lost to follow-up
1 Had an abnormal test
procedure result
2 Died
131 Discontinued the study drug
32 Had an abnormal laboratory
value
31 Had an adverse event
30 Withdrew consent
18 Had an unsatisfactory
therapeutic effect
8 Had a protocol violation
6 Had an abnormal test result
3 Had administrative problems
2 Were lost to follow-up
1 Died
369 Completed the study
345 Were still receiving the
study drug
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80 Discontinued the study drug
20 Had an abnormal laboratory
value
15 Had an adverse event
17 Withdrew consent
8 Had an unsatisfactory
therapeutic effect
8 Had a protocol violation
3 Had an abnormal test result
3 Had administrative problems
6 Were lost to follow-up
115 Discontinued the study drug
5 Had an abnormal laboratory
value
24 Had an adverse event
31 Withdrew consent
36 Had an unsatisfactory
therapeutic effect
5 Had a protocol violation
3 Had an abnormal test result
4 Had administrative problems
5 Were lost to follow-up
2 Died
56 Discontinued the study 
17 Withdrew consent
13 Had an adverse event
9 Had an abnormal laboratory
value
6 Had an unsatisfactory
therapeutic effect
5 Had a protocol violation
5 Were lost to follow-up
1 Had an abnormal test
procedure result
Figure 1. Enrollment, Randomization, and Follow-up of Study Patients.
Among the 292 patients who were assessed for eligibility but were not enrolled, some were excluded for more than one 
reason. For one patient receiving 1.25 mg of fingolimod daily who completed the study while receiving the study drug, 
the status was incorrectly recorded by the investigator as having discontinued the study while still receiving the study drug. 
Patients who discontinued the study drug include those who discontinued the study; the correct status is shown here.
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Mean 37.4±8.9 36.6±8.8 37.2±8.6
Median (range) 38.0 (17–55) 36.0 (18–55) 37.0 (18–55)
Female sex — no. (%) 295 (68.8) 296 (69.6) 298 (71.3)
Disease and treatment history
Time from first MS symptom to randomization — yr
Mean 8.4±6.9 8.0±6.6 8.1±6.4
Median (range) 6.9 (0–37) 6.6 (0–35) 7.0 (0–32)
Relapses — no.
Within previous yr
Mean 1.5±0.8 1.5±0.8 1.4±0.7
Median (range) 1.0 (0–6) 1.0 (0–5) 1.0 (0–6)
Within previous 2 yr
Mean 2.1±1.3 2.1±1.1 2.2±1.2
Median (range) 2.0 (1–10) 2.0 (1–11) 2.0 (1–10)
EDSS score†
Mean 2.4±1.4 2.3±1.3 2.5±1.3
Median (range) 2.0 (0–5.5) 2.0 (0–5.5) 2.0 (0–5.5)
No history of disease-modifying treatment — no. (%) 259 (60.4) 244 (57.4) 249 (59.6)
Features on MRI‡
Absence of gadolinium-enhancing lesions — no. (%) 257 (60.6) 263 (62.0) 262 (63.0)
No. of gadolinium-enhancing lesions on T1-weighted 
images 
Mean 1.8±4.7 1.6±5.6 1.3±2.9
Median (range) 0 (0–50) 0 (0–84) 0 (0–26)
Volume of lesions on T2-weighted images — mm3
Mean 6829±8491 6128±7623 6162±7085
Median (range) 3557 (0–47,734) 3303 (0–47,148) 3416 (0–37,148)
Volume of hypointense lesions on T1-weighted images 
— mm3
Mean 2114±3220 1898±2854 1962±3131
Median (range) 860 (0–25,886) 814 (0–22,378) 811 (0–20,956)
Normalized brain volume — ml
Mean 1511±86 1521±83 1512±85
Median (range) 1515 (1217–1764) 1529 (1144–1734) 1515 (1230–1723)
* Plus–minus values are means ±SD. There were no significant between-group differences at baseline for any characteris-
tic. MS denotes multiple sclerosis.
† The Expanded Disability Status Scale (EDSS) ranges from 0 to 10, with higher scores indicating greater disability.
‡ MRI data were available for 424 patients in each of the fingolimod groups and for 416 patients in the placebo group. 
The means and medians were calculated on the basis of all images, not just those showing lesions.
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at a dose of 1.25 mg (occurring in 14.2% of pa-
tients) than with fingolimod at a dose of 0.5 mg 
(occurring in 7.5%) or with placebo (occurring in 
7.7%). Serious adverse events were reported for 
10.1% of patients receiving 0.5 mg of fingolimod, 
11.9% of those receiving 1.25 mg of fingolimod, 
and 13.4% of those receiving placebo. The most 
common serious adverse events, each reported for 
eight patients, were bradycardia, multiple sclero-
sis relapse, and basal-cell carcinoma. All other seri-
ous adverse events occurred in four or fewer pa-
tients (<1%) in any study group. The seven episodes 
of bradycardia in the two fingolimod groups (four 
in the 0.5-mg group and three in the 1.25-mg 
group) were reported during the monitoring period 
after administration of the first dose. Six of these 
events were asymptomatic; the patients continued 
to receive fingolimod and the episodes were re-
ported as serious adverse events because the pro-
tocol-defined discharge criteria for the first-dose 
monitoring period were not met.
Three deaths occurred during the study, two 
with placebo and one with 1.25 mg of fingolimod. 
The causes of death in the placebo group were 
pulmonary embolism and a traffic accident, and 
the cause in the fingolimod group was suicide.
Infections
The overall incidence of infection was similar in 
the fingolimod and placebo groups (69 to 72%); 
serious infections occurred in 1.6 to 2.6% of pa-
tients. Urinary tract infection was the only seri-
ous infection reported in more than one patient 
(reported in two patients in the group receiving 
0.5 mg of fingolimod). Herpesvirus infections were 
reported in similar proportions of patients across 
the three study groups (Table 3). Of these infec-
tions, herpes zoster was reported in seven patients 
receiving 0.5 mg of fingolimod, three receiving 
1.25 mg of fingolimod, and four receiving place-
bo. Two cases of herpesvirus infection were clas-
sified as serious adverse events: one case of genital 
herpes (in a patient receiving 1.25 mg of fingoli-
mod) and one case of herpes simplex labialis (in 
a patient receiving 0.5 mg of fingolimod).
Lower respiratory tract infections (including 
bronchitis and pneumonia) were more common 
with fingolimod than with placebo (occurring in 
41 patients [9.6%] receiving 0.5 mg of fingoli-
mod and 49 patients [11.4%] receiving 1.25 mg 
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Cardiovascular Events
Transient, dose-related decreases in the heart rate 
occurred after the first dose of fingolimod was 
administered, a finding that is consistent with 
previous clinical experience.13,15,24,27 Heart-rate de-
creases started 2 hours after receipt of the first 
dose, reaching the nadir after 4 to 5 hours, with 
attenuation beginning at 6 hours. The maximal 
reduction in the mean resting pulse rate, as com-
pared with the baseline value, was 8 beats per min-
ute 5 hours after the first dose of 0.5 mg of fin-
golimod and 10 beats per minute 4 hours after the 
first dose of 1.25 mg of fingolimod. Bradycardia 
(including the seven cases classified as serious ad-
verse events) was reported in 9 patients receiving 
0.5 mg of fingolimod, 14 receiving 1.25 mg of fin-
golimod, and 3 receiving placebo (Table 3). The 
majority of these events in the fingolimod groups 
occurred during the monitoring period after the 
first dose was administered (in 8 and 12 patients 
receiving 0.5 mg and 1.25 mg of fingolimod, re-
spectively). Of these, six events were symptomatic 
(characterized by dizziness, chest discomfort, or 
palpitations) and all resolved with 24 hours; two 
patients received treatment for bradycardia.
First- and second-degree atrioventricular block 
was infrequently reported as an adverse event 
(Table 3). However, electrocardiography performed 
on day 1 revealed first-degree atrioventricular 
block in 20 patients receiving 0.5 mg of fingoli-
mod, in 37 receiving 1.25 mg of fingolimod, and 
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Figure 2. Study End Points, According to Study Group.
Panel A shows Kaplan–Meier estimates for the time to 
a first relapse, and Panel B shows Kaplan–Meier esti-
mates for the time to disability progression, confirmed 
after 3 months, as measured with the Expanded Dis-
ability Status Scale (EDSS). Panel C shows the propor-
tions of patients free from gadolinium-enhancing  
lesions and the mean (±SD) number of gadolinium- 
enhancing lesions at baseline and at 6, 12, and 24 
months. Data on gadolinium-enhancing lesions were 
available for 416 patients assigned to receive placebo, 
424 assigned to receive 1.25 mg of fingolimod, and  
424 assigned to receive 0.5 mg of fingolimod, respec-
tively, at baseline; 373, 388, and 403, respectively,  
at 6 months; 356, 376, and 394, respectively, at 12 
months; and 332, 343, and 369, respectively, at 24 
months. The P values for the proportions were ob-
tained with the use of a logistic-regression model,  
with adjustment for study group, country, and number 
of lesions at baseline. 
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tricular block (also known as Mobitz I periodic-
ity) was identified on electrocardiography on day 
1 in one patient receiving 0.5 mg of fingolimod 
and in four patients receiving 1.25 mg of fingoli-
mod. Second-degree atrioventricular block was 
symptomatic in one patient (in the 1.25-mg group), 
who had shortness of breath and palpitations 
(Table 3). No clinically notable effect on heart rate 
or atrioventricular conduction was seen with con-
tinued use of fingolimod.
Starting during month 2, the mean systolic and 
diastolic blood pressures obtained while the pa-
tient was seated increased from the baseline val-
ues; at month 24, they had increased by 1.9 and 
0.7 mm Hg, respectively, with 0.5 mg of fingoli-
mod and by 3.6 and 2.1 mm Hg, respectively, with 
1.25 mg of fingolimod and had decreased by 
0.4 and 0.5 mm Hg, respectively, in the placebo 
group.
Ophthalmic Events
Macular edema was diagnosed in seven patients, 
all of whom were receiving 1.25 mg of fingolimod. 
Three of these events were reported as serious 
adverse events (Table 3). Five of these seven cases 
of macular edema occurred within 3 months af-
ter the start of therapy. Six cases resolved within 
1 to 6 months after treatment was discontinued. 
Mean visual acuity and central foveal thickness re-
mained stable in all patients throughout the study.
Neoplasms
Malignant neoplasms were reported in 4 patients 
receiving 0.5 mg of fingolimod, 4 receiving 1.25 mg 
of fingolimod, and 10 receiving placebo (Table 3). 
All 11 skin cancers (basal-cell carcinoma, malig-
nant melanoma, or Bowen’s disease) that occurred 
(3 cases with 1.25-mg fingolimod, 4 with 0.5-mg 
fingolimod, and 4 with placebo) were removed suc-
cessfully.
Laboratory Abnormalities
At 1 month, peripheral-blood lymphocyte counts 
were reduced from the baseline counts by an av-
erage of 73% with 0.5 mg of fingolimod and 76% 
with 1.25 mg of fingolimod, remaining stable 
thereafter (see the Supplementary Appendix). These 
were not reported as adverse events by the inves-
tigators, who remained unaware of the actual val-
ues unless they dropped to less than 0.2×109 per 
liter. Increases in the alanine aminotransferase 
level to three times the upper limit of the normal 
range or more were more frequent in the fingoli-
mod groups (reported in 8.5% of patients in the 
0.5-mg group and 12.5% in the 1.25-mg group) 
than in the placebo group (1.7%) and occurred pre-
dominantly in men. One patient receiving 0.5 mg 
of fingolimod had an increase in the alanine ami-
notransferase level to more than 10 times the 
upper limit of the normal range. Elevated liver-
enzyme levels returned to normal in all patients, 
even in the few who continued the study treatment. 
In all three groups, bilirubin levels remained sta-
ble, with no clinically relevant changes during the 
study.
Discussion
This 2-year study showed that as compared with 
placebo, both doses of fingolimod tested reduced 
the annualized relapse rate. Disability progres-
sion was also significantly reduced in patients 
receiving fingolimod as compared with those re-
ceiving placebo. These clinical findings are sup-
ported by the results regarding the MRI end points 
and are in line with the results of a 6-month, 
placebo-controlled, phase 2 study13 and a 1-year, 
phase 3 study comparing fingolimod with an 
active drug (intramuscular interferon beta-1a) 
(TRANSFORMS).15
The 30% reduction in the rate of reduction 
of brain volume in this study — detected as 
early as 6 months after initiation of the study 
drug and also seen over a 12-month period in 
TRANSFORMS15 — is an interesting corollary to 
the clinical findings. It remains to be established 
whether this effect is due to the reduction in in-
flammatory activity or reflects direct interactions 
between the drug and sphingosine-1-phosphate 
receptors on neural cells,6,7,10 as suggested by stud-
ies in animals and by in vitro observations.6-12
This study also provides important 2-year, pla-
cebo-controlled information about the safety of 
fingolimod. As medications used to treat multi-
ple sclerosis become increasingly potent, attention 
to safety findings is paramount. Possible concerns 
include infections, cardiovascular effects, macular 
edema, and elevated liver-enzyme levels. The safety 
profile warrants further longer-term assessment.
As expected on the basis of its mechanism of 
action, fingolimod treatment led to a reduction 
in circulating lymphocytes of approximately 70% 
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Table 3. Adverse Events in the Safety Population, According to Study Group.
Event Fingolimod Placebo (N = 418)
1.25 mg (N = 429) 0.5 mg (N = 425)
no. of patients (%)
All events
At least one adverse event 404 (94.2) 401 (94.4) 387 (92.6)
Any adverse event leading to discontinuation of study 
drug*
61 (14.2) 32 (7.5) 32 (7.7)
Any serious adverse event 51 (11.9) 43 (10.1) 56 (13.4)
Death 1 (0.2) 0 2 (0.5)
Frequent or special-interest adverse events†
Infections
Upper respiratory tract infection 206 (48.0) 212 (49.9) 211 (50.5)
Nasopharyngitis 112 (26.1) 115 (27.1) 115 (27.5)
Sinusitis 27 (6.3) 28 (6.6) 19 (4.5)
Pharyngitis 25 (5.8) 27 (6.4) 24 (5.7)
Rhinitis 18 (4.2) 25 (5.9) 25 (6.0)
Influenza virus infection 40 (9.3) 55 (12.9) 41 (9.8)
Lower respiratory tract or lung infection 49 (11.4) 41 (9.6) 25 (6.0)
Bronchitis 39 (9.1) 34 (8.0) 15 (3.6)
Pneumonia 8 (1.9) 4 (0.9) 3 (0.7)
Herpesvirus infection‡ 25 (5.8) 37 (8.7) 33 (7.9)
Urinary tract infection 21 (4.9) 34 (8.0) 47 (11.2)
Nervous system disorders
Headache 114 (26.6) 107 (25.2) 96 (23.0)
Dizziness 30 (7.0) 31 (7.3) 23 (5.5)
Paresthesia 17 (4.0) 23 (5.4) 18 (4.3)
Abnormal laboratory liver-function test§ 80 (18.6) 67 (15.8) 21 (5.0)
Fatigue 47 (11.0) 48 (11.3) 45 (10.8)
Musculoskeletal disorders
Back pain 45 (10.5) 50 (11.8) 29 (6.9)
Arthralgia 27 (6.3) 30 (7.1) 33 (7.9)
Pain in extremity 24 (5.6) 28 (6.6) 28 (6.7)
Gastrointestinal disorders
Diarrhea 40 (9.3) 50 (11.8) 31 (7.4)
Nausea 38 (8.9) 38 (8.9) 36 (8.6)
Respiratory disorders
Cough 37 (8.6) 43 (10.1) 34 (8.1)
Dyspnea 23 (5.4) 30 (7.1) 19 (4.5)
Oropharyngeal pain 17 (4.0) 29 (6.8) 29 (6.9)
Blood and lymphatic system disorders
Leukopenia 27 (6.3) 12 (2.8) 1 (0.2)
Lymphopenia 23 (5.4) 15 (3.5) 2 (0.5)
Cardiovascular disorders
Hypertension 27 (6.3) 26 (6.1) 16 (3.8)
Bradycardia, bradyarrhythmia, or sinus bradycardia 14 (3.3) 9 (2.1) 3 (0.7)
Atrioventricular block
First degree 5 (1.2) 2 (0.5) 2 (0.5)
Second degree 1 (0.2) 0 1 (0.2)
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Table 3. (Continued.)
Event Fingolimod Placebo (N = 418)
1.25 mg (N = 429) 0.5 mg (N = 425)
no. of patients (%)
Psychiatric disorders
Depression 26 (6.1) 33 (7.8) 28 (6.7)
Insomnia 16 (3.7) 21 (4.9) 25 (6.0)
Hypercholesterolemia 26 (6.1) 24 (5.6) 26 (6.2)
Weight increase 14 (3.3) 14 (3.3) 22 (5.3)
Vertigo 18 (4.2) 18 (4.2) 21 (5.0)
Macular edema 7 (1.6) 0 0
Serious adverse events¶
Cardiovascular disorders
Bradycardia 3 (0.7) 4 (0.9) 1 (0.2)
Myocardial infarction 0 0 2 (0.5)
Neoplasms
Basal-cell carcinoma 1 (0.2) 4 (0.9) 3 (0.7)
Breast cancer 1 (0.2) 0 3 (0.7)
Malignant melanoma 1 (0.2) 0 1 (0.2)
Bowen’s disease 1 (0.2) 0 0
Cervical carcinoma, stage 0 0 0 1 (0.2)
Endometrial cancer 0 0 1 (0.2)
Prostate cancer 0 0 1 (0.2)
Nervous system disorders
MS relapse‖ 3 (0.7) 4 (0.9) 1 (0.2)
Epilepsy 2 (0.5) 0 0
Headache 2 (0.5) 0 0
General disorders
Chest pain 0 4 (0.9) 2 (0.5)
Macular edema 3 (0.7) 0 0
Laboratory evaluation
Abnormal liver-function test 2 (0.5) 0 1 (0.2)
Lymphopenia 2 (0.5) 0 0
Depression 2 (0.5) 0 1 (0.2)
Musculoskeletal disorders
Back pain 0 2 (0.5) 1 (0.2)
Intervertebral disk protrusion 0 0 2 (0.5)
Abortion 0 0 3 (0.7)
Urinary tract infection 0 2 (0.5) 0
* “Any adverse event leading to discontinuation of the study drug” includes events occurring in patients whose primary 
or secondary reason for discontinuing the study drug was an adverse event (including abnormal laboratory findings).
† “Frequent adverse events” includes those reported in 5% or more of patients in any group. 
‡ The terms used to report herpesvirus infection included oral herpes, herpesvirus infection, herpes simplex virus infec-
tion, herpes zoster, genital herpes, and herpes dermatitis.
§ The terms used to report an abnormal laboratory liver-function test included increased levels of alanine aminotrans-
ferase, aspartate aminotransferase, γ-glutamyltransferase, hepatic enzyme, and aminotransferases, and abnormal  
liver-function tests or γ-glutamyltransferase levels.
¶ “Serious adverse events” includes those reported in two or more patients in any group or of special interest.
‖ “MS relapse” includes both events related to the worsening of multiple sclerosis (MS) and MS relapses. See the 
Supplementary Appendix for further details.
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in the present study. The overall incidence of in-
fection was similar across the three study groups, 
with the exception of lower respiratory tract in-
fections, which were more common with fingoli-
mod than with placebo. Although similar pro-
portions of patients in the three groups had 
herpesvirus infections, reactivation of latent her-
pes remains a potential risk with immunomodu-
latory therapy; two fatal herpes infections occurred 
in TRANSFORMS with the 1.25-mg dose of fin-
golimod.15
Cardiovascular effects of fingolimod included 
slowing of the heart rate and atrioventricular con-
duction block at the time of the first dose. These 
effects appear to be dose-dependent and specifi-
cally related to the binding of the drug to sphin-
gosine-1-phosphate receptors in cardiac tissue.28 
Interactions with sphingosine-1-phosphate recep-
tors in smooth muscle may account for the mild 
increase in blood pressure seen during long-term 
treatment. The long-term relevance of this find-
ing is unclear.
Fingolimod was infrequently associated with 
macular edema, which resolved with discontinu-
ation of the drug. The frequency of this compli-
cation and possible implications during long-term 
use are not known.
Elevations in liver-enzyme levels were common 
findings in this study and in earlier studies.13,24 
These elevated values resolved after fingolimod 
was discontinued.13,15,24
Our findings do not suggest an increased risk 
of cancer with the use of fingolimod. However, 
further long-term observation is necessary, since 
the risk of cancer is potentially increased by the 
use of any immunomodulatory agent.
In conclusion, oral fingolimod as compared 
with placebo had superior efficacy in this 24-month 
study involving patients with relapsing–remitting 
multiple sclerosis. Rates of relapse, progression 
of clinical disability, and MRI evidence of inflam-
matory lesion activity and tissue destruction were 
all significantly reduced with the use of fingoli-
mod. The two doses of fingolimod had similar 
efficacy, and adverse events may be less frequent 
with the 0.5-mg dose than with the 1.25-mg dose. 
Thorough observation and long-term follow-up are 
necessary for a more informed assessment of the 
benefits and risks of this new treatment option 
for relapsing multiple sclerosis.
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